Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab

References

• JemalASiegelRWardECancer statistics, 2008CA Cancer J Clin200858719618287387
   PubMed Web of Science ®Google Scholar
• GeorgeDJKaelinWGJrThe von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancerN Engl J Med200334941942112890838
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTETomczakPSunitinib versus interferon alfa in metastatic renal-cell carcinomaN Engl J Med200735611512417215529
   PubMed Web of Science ®Google Scholar
• HudesGCarducciMTomczakPTemsirolimus, interferon alfa, or both for advanced renal-cell carcinomaN Engl J Med20073562271228117538086
   PubMed Web of Science ®Google Scholar
• EscudierBPluzanskaAKoralewskiPBevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialLancet20073702103211118156031
   PubMed Web of Science ®Google Scholar
• RiniBIHalabiSRosenbergJEBevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206J Clin Oncol2008265422542818936475
   PubMed Web of Science ®Google Scholar
• GnarraJRLermanMIZbarBLinehanWMGenetics of renalcell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesisSemin Oncol199522387855617
   PubMed Web of Science ®Google Scholar
• JaakkolaPMoleDRTianYMTargeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylationScience200129246847211292861
   PubMed Web of Science ®Google Scholar
• ShuinTKondoKTorigoeSFrequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomasCancer Res199454285228558187067
   PubMed Web of Science ®Google Scholar
• KondoKYaoMYoshidaMComprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parametersGenes Chromosomes Cancer200234586811921283
   PubMed Web of Science ®Google Scholar
• GnarraJRToryKWengYMutations of the VHL tumour suppressor gene in renal carcinomaNat Genet1994785907915601
   PubMed Web of Science ®Google Scholar
• CliffordSCProwseAHAffaraNABuysCHMaherERInactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesisGenes Chromosomes Cancer1998222002099624531
   PubMed Web of Science ®Google Scholar
• MichaelsonICThe mode of development of the vascular system of the retina, with some observations on its significance for certain retinal diseasesTrans Ophthalmol Soc U K194868137180
   Google Scholar
• LeungDWCachianesGKuangWJGoeddelDVFerraraNVascular endothelial growth factor is a secreted angiogenic mitogenScience1989246130613092479986
   PubMed Web of Science ®Google Scholar
• FerraraNHenzelWJPituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cellsBiochem Biophys Res Commun19891618518582735925
   PubMed Web of Science ®Google Scholar
• VincentiVCassanoCRocchiMPersicoGAssignment of the vascular endothelial growth factor gene to human chromosome 6p21.3Circulation199693149314958608615
   PubMed Web of Science ®Google Scholar
• TischerEMitchellRHartmanTThe human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicingJ Biol Chem199126611947119541711045
   PubMed Web of Science ®Google Scholar
• FerraraNDavis-SmythTThe biology of vascular endothelial growth factorEndocr Rev1997184259034784
   PubMed Web of Science ®Google Scholar
• RuhrbergCGerhardtHGoldingMSpatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesisGenes Dev2002162684269812381667
   PubMed Web of Science ®Google Scholar
• CarmelietPNgYSNuyensDImpaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188Nat Med1999549550210229225
   PubMed Web of Science ®Google Scholar
• FukumuraDXavierRSugiuraTTumor induction of VEGF promoter activity in stromal cellsCell1998947157259753319
   PubMed Web of Science ®Google Scholar
• DamesSAMartinez-YamoutMDe GuzmanRNDysonHJWrightPEStructural basis for HIF-1 alpha /CBP recognition in the cellular hypoxic responseProc Natl Acad Sci U S A2002995271527611959977
   PubMed Web of Science ®Google Scholar
• KibelAIliopoulosODeCaprioJAKaelinWBinding of the von Hippel-Lindau tumor suppressor protein to Elongin B and CScience1995269144414467660130
   PubMed Web of Science ®Google Scholar
• PoltorakZCohenTSivanRVEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrixJ Biol Chem19972721517158
   Web of Science ®Google Scholar
• RobertsWGPaladeGEIncreased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factorJ Cell Sci1995108236923797673356
   PubMed Web of Science ®Google Scholar
• BatesDOLodwickDWilliamsBVascular endothelial growth factor and microvascular permeabilityMicrocirculation19996839610466111
   PubMed Web of Science ®Google Scholar
• PrestaLGChenHO’ConnorSJHumanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disordersCancer Res199757459345999377574
   PubMed Web of Science ®Google Scholar
• WangYFeiDVanderlaanMSongABiological activity of bevacizumab, a humanized anti-VEGF antibody in vitroAngiogenesis2004733534515886877
   PubMedGoogle Scholar
• GerberHPFerraraNPharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studiesCancer Res20056567168015705858
   PubMed Web of Science ®Google Scholar
• RoweDHHuangJKaytonMLAnti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms’ tumorJ Pediatr Surg200035303310646769
   PubMed Web of Science ®Google Scholar
• GordonMSMargolinKTalpazMPhase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancerJ Clin Oncol20011984385011157038
   PubMed Web of Science ®Google Scholar
• MargolinKGordonMSHolmgrenEPhase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety dataJ Clin Oncol20011985185611157039
   PubMed Web of Science ®Google Scholar
• YangJCHaworthLSherryRMA randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancerN Engl J Med200334942743412890841
   PubMed Web of Science ®Google Scholar
• ElarajDWhiteDESteinbergSMHayworthLRosenbergSAYangJCA pilot study of antiaglogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinomaJ Immunotherapy200427259264
   PubMed Web of Science ®Google Scholar
• YuanFChenYDellianMSafabakhshNFerraraNJainRKTime-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibodyProc Natl Acad Sci U S A19969314765147708962129
   PubMed Web of Science ®Google Scholar
• YangJCBevacizumab for patients with metastatic renal cancer: an updateClin Cancer Res2004106367S6370S15448032
   PubMed Web of Science ®Google Scholar
• Viloria-PetitACrombetTJothySAcquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesisCancer Res2001615090510111431346
   PubMed Web of Science ®Google Scholar
• KnebelmannBAnanthSCohenHTSukhatmeVPTransforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressorCancer Res1998582262319443397
   PubMed Web of Science ®Google Scholar
• HainsworthJDSosmanJASpigelDRTreatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinibJ Clin Oncol2005237889789616204015
   PubMed Web of Science ®Google Scholar
• HainsworthJDSpigelDRSosmanJATreatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trialClin Genitourin Cancer2007542743218272024
   PubMed Web of Science ®Google Scholar
• RowinskyEKSchwartzGHGollobJASafety, pharmacokinetics, and activity oFABX-EGF, a Fully human anti-epidermal growth Factor receptor monoclonal antibody in patients with metastatic renal cell cancerJ Clin Oncol2004223003301515210739
   PubMed Web of Science ®Google Scholar
• BukowskiRMKabbinavarFFFiglinRARandomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancerJ Clin Oncol2007254536454117876014
   PubMed Web of Science ®Google Scholar
• MotzerRJBacikJMurphyBAInterferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinomaJ Clin Oncol20022028929611773181
   PubMed Web of Science ®Google Scholar
• RiniBIHalabi RosenbergSJBevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206J Clin Oncol200927 18ssuppl abstr LBA5019.
   Google Scholar
• EscudierBJBellmuntJNegrierSFinal results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC)J Clin Oncol200927 15ssuppl abstr 5020.
   Google Scholar
• KoJSZeaAHRiniBISunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patientsClin Cancer Res2009152148245719276286
   PubMed Web of Science ®Google Scholar
• GabrilovichDIIshidaTNadafSAntibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell functionClin Cancer Res199952963297010537366
   PubMed Web of Science ®Google Scholar
• TamirAJordanWJRitterMInterferon-alpha2a is sufficient for promoting dendritic cell immunogenicityClin Exp Immunol200514247148016297159
   PubMed Web of Science ®Google Scholar
• DinneyCPBielenbergDRPerrottePInhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-B administrationCancer Res1998588088149485039
   PubMed Web of Science ®Google Scholar
• MelicharBKoralewskiPRavaudAFirst-line bevacizumab combined with reduced dose interferon-a2a is active in patients with metastatic renal cell carcinomaAnn Oncol2008191470147618408224
   PubMed Web of Science ®Google Scholar
• EscudierBEisenTStadlerWMSorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III Treatment Approaches in Renal Cancer Global Evaluation TrialJ Clin Oncol2009271919029415
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTETomczakPOverall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell CarcinomaJ Clin Oncol2009273584359019487381
   PubMed Web of Science ®Google Scholar
• CoonJSLiuZHoyleMSunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectivenessBr J Cancer200910123824319568242
   PubMed Web of Science ®Google Scholar
• BenedictACharbonneauCHidiJKimSTNegrierSEconomic evaluation of sunitinib, sorafenib, bevacizumab/interferon-alfa or temsirolimus in first-line treatment of metastatic renal cell carcinoma – a indirect comparisonJ Clin Oncol200826520suppl abstr 5048.
   Google Scholar
• MickischGGoreMEscudierBProcopioGWalzerSNuijtenMCosts of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinibBr J Cancer2008 (Epub Nov 17, 2009).
   Web of Science ®Google Scholar
• National Institute for Clinical Excellence (NICE)Technology Appraisal Guidance 169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma; issued March 2009 http//www.nice.org.uk/guidance/TA169.
   Google Scholar
• ErnstoffMSReganMMMcDermottDFFirst-line treatment with bevacizumab (B) and high dose (HD) bolus aldesleukin (IL-2) in metastatic renal cell carcinoma (mRCC) patients (Pts)J Clin Oncol2007ASCO Annual Meeting Proceedings Part 12518S abstr 15524.
   Google Scholar
• van der VlietHJKoonHBEffects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancerClin Cancer Res2007132100210817404092
   PubMed Web of Science ®Google Scholar
• GarciaJARiniBIMekhailTA phase II trial of low-dose interleukin-2 (IL-2) and bevacizumab in patients with metastatic renal cell carcinoma (mRCC)J Clin Oncol2007ASCO Annual Meeting Proceedings Part I2518S620 Suppl abstr 5103.
   Google Scholar
• DePrimoSEBelloCSurrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinibAnn Oncol200718Suppl 101119
   Web of Science ®Google Scholar
• FeldmanDBaumMGinsbergMPhase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinomaJ Clin Oncol2009271432143919224847
   PubMed Web of Science ®Google Scholar
• RiniBIGarciaJACooneyMMA phase I study of sunitinib plus bevacizumab in advanced solid tumorsClin Cancer Res2009156277628319773375
   PubMed Web of Science ®Google Scholar
• AzadNSPosadasEMKwitkowskiVECombination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activityJ Clin Oncol2008263709371418669456
   PubMed Web of Science ®Google Scholar
• SosmanJAFlahertyKTAtkinsMBUpdated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC)J Clin Oncol200826520 suppl Abstract 5011.
   Google Scholar
• WhorfRCHainsworthJDSpigelDRPhase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC)J Clin Oncol200826520 suppl abstr 5010.
   Google Scholar
• Ayral-kaloustianSLucasGJZaskGCHybrid inhibitors of phoisphatiylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugatesJ Med Chem2009 [Epub ahead of print 23 Nov].
   Web of Science ®Google Scholar
• MerchanJRLiuGFitchTPhase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity resultsJ Clin Oncol20072518S abstr 5034.
   Google Scholar
• Bevacizumab, sorafenib, and temsirolimus in treating patients with metastatic kidney cancer ClinicalTrials.gov, NCT00378703.
   Google Scholar
• Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma (TORAVA) ClinicalTrials.gov, NCT 00619268.
   Google Scholar
• JonaschEWoodCGMatinSFPhase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinomaJ Clin Oncol2009274076408119636008
   PubMed Web of Science ®Google Scholar
• KabbinavarFFHambletonJMassRDCombined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancerJ Clin Oncol2005233706371215867200
   PubMed Web of Science ®Google Scholar
• RugoHSBevacizumab in the treatment of breast cancer: Rationale and current dataOncologist20049Suppl 1434915178815
   PubMed Web of Science ®Google Scholar
• JohnsonDHFehrenbacherLNovotnyWFRandomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancerJ Clin Oncol2004222184219115169807
   PubMed Web of Science ®Google Scholar